CLAIMS:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 and R^2 independently represent halogen, hydroxy, cyano, nitro, oxo, haloC_{1-6} alkyl, polyhaloC_{1-6} alkyl, haloC_{1-6} alkoxy, polyhaloC_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, aryl, heteroaryl, heterocyclyl, arylC_{1-6} alkyl, heteroarylC_{1-6} alkyl, heterocyclylC_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, aryloxy, -CO-aryl, -CO-heterocyclyl, -CO-heteroaryl, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylaminosulfonyl, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group $NR^{15}R^{16}$, $-NR^{15}CO$-aryl, $-NR^{15}CO$-heterocyclyl, $-NR^{15}CO$-heteroaryl, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-NR^{15}SO_2R^{16}$ or $-SO_2NR^{15}R^{16}$, wherein R^{15} and R^{16} independently represent hydrogen or C_{1-6} alkyl; wherein said aryl, heteroaryl and heterocyclyl groups of R^1 and R^2 may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different and which are selected from halogen, C_{1-6} alkyl, C_{1-6} alkoxy, oxo, CF_3, OCF_3, CN, C_{1-6} alkanoyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylamido or C_{1-6} alkylsulfonamido;

a and b independently represent 0, 1 or 2, such that a and b cannot both represent 0;

⁼⁼⁼⁼⁼ is a single or double bond;

R^3 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;

m and n independently represent 0, 1 or 2;

p represents an integer from 0 to 3, such that when p is an integer greater than 1, two R^1 groups may instead be linked to form a heterocyclyl group;

R^4 represents $-(CH_2)_q-NR^{11}R^{12}$ or a group of formula (i):



(i)

wherein q is 2, 3 or 4;

R^{11} and R^{12} independently represent C_{1-6} alkyl or together with the nitrogen atom to which they are attached represent an N-linked heterocyclic group optionally substituted by one or two R^{17} groups;
R^{13} represents hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, -C_{1-6} alkyl-aryl or heterocyclyl;
R^{14} and R^{17} independently represent halogen, C_{1-6} alkyl, haloC_{1-6} alkyl, OH, diC_{1-6} alkylamino or C_{1-6} alkoxy;
f and k independently represent 0, 1 or 2;
g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0;
or solvates thereof.

2. A compound as defined in claim 1 wherein R^1 represents halogen, hydroxy, cyano, nitro, -$NR^{15}R^{16}$, -$NR^{15}COR^{16}$, polyhaloC_{1-6} alkyl, heterocyclyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkanoyl, arylsulfonamido, arylaminosulfonyl, –$NR^{15}SO_2R^{16}$, -$SO_2NR^{15}R^{16}$, –CO-heterocyclyl or two R^1 groups are linked to form a heterocyclyl group.

3. A compound as defined in claim 2 wherein p represents 1 and R^1 represents fluoro or cyano.

4. A compound as defined in claim 1 wherein p represents 0.

5. A compound as defined in any one of claims 1 to 4 wherein m represents 1 and R^2 represents C_{1-6} alkyl, arylC_{1-6} alkyl, aryl or heteroaryl.

6. A compound as defined in any one of claims 1 to 4 wherein m represents 0.

7. A compound as defined in any one of claims 1 to 6 wherein n represents 1 and R^3 represents halogen or polyhaloC_{1-6} alkyl.

8. A compound as defined in any one of claims 1 to 6 wherein n represents 0.

9. A compound as defined in any one of claims 1 to 8 wherein a is 1 and b is 0.

10. A compound as defined in any one of claims 1 to 9 wherein ------- is a single bond.

11. A compound as defined in any one of claims 1 to 10 wherein –O-R^4 is present on the phenyl group at the 4-position.

12. A compound as defined in any one of claims 1 to 11 wherein R^4 represents -$(CH_2)_q$-$NR^{11}R^{12}$, q represents 3 and $NR^{11}R^{12}$ represents unsubstituted piperidine.

13. A compound as defined in any one of claims 1 to 11 wherein R^4 represents a group of formula (i), f represents 0, h represents 1, g represents 2, k represents 0 and R^{13} represents C_{3-8} cycloalkyl.

14. A compound according to claim 1 which is
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-3,4-dihydro-1H-isoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-bromoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]indole;
5-Fluoro-2-methyl-N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-indole;
5-Methoxy-2-methyl-N-[4-(3-piperidin-1-ylpropoxy)benzoyl]-indole;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-fluoroindoline;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2-methylindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1,2,3,4-tetrahydroquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-nitroisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-aminoisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-(1-succinimido)-isoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-(2-oxo-pyrrolidin-1-yl)-isoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)-2-trifluoromethyl-benzoyl]isoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-cyano-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-cyano-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-methylsulfonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-3,3-dimethylindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-methoxy-6-trifluoromethyl-indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(dimethylaminosulfonyl)-indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(methylsulfinyl)-indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(methylsulfonyl)-indoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-acetyl-indoline;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-2-methyl-1,2,3,4-tetrahydroquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-methyl-1,2,3,4-tetrahydroquinoline;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-benzyl-1,2,3,4-tetrahydroisoquinoline;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-(phenylsulfonamido)-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-(phenylaminosulfonyl)-1,2,3,4-tetrahydroisoquinoline;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-methoxyisoindoline;

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-trifluoromethylisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-acetyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-acetylamino-8-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-methylsulfonamido-8-methoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]- 6,7,8,9-tetrahydro-5*H*-[1,3]dioxolo[4,5-*h*][3]benzazepine;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-6,7-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-8,9-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-7,9-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-phenyl-7-hydroxy-8-methylsulfonyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-(4-methoxyphenyl)-6,9-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-thienyl-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-bromo-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
(±)-N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-1-(4-i-propylsulfonyl)-6-chloro-7,8-dimethoxy-2,3,4,5-tetrahydro-1*H*-3-benzazepine;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-fluoro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-6-chloro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7,8-dichloro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-8-chloro-1,2,3,4-tetrahydroisoquinoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-7-cyano-2,3,4,5-tetrahydro-1*H*-3-benzazepine;N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-4-fluoroisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-cyanoisoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-[(pyrrolidin-1-yl)carbonyl]isoindoline;
N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-5-[(morpholin-4-yl)carbonyl]isoindoline;
N-[2-Chloro-4-(3-Piperidin-1-ylpropoxy)benzoyl]isoindoline;
N-{2-Chloro-4-[(1-isopropyl-4-piperidinyl)oxy]benzoyl}isoindoline;
N-{2-Chloro-4-[(1-isopropyl-4-piperidinyl)oxy]benzoyl}-5-fluoro-isoindoline;
N-{2-Chloro-4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoyl}isoindoline; or
N-{2-Chloro-4-[(1-cyclobutyl-4-piperidinyl)oxy]benzoyl}-5-fluoro-isoindoline
or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 1 which is:

N-[4-(3-Piperidin-1-ylpropoxy)-benzoyl]-5-fluoroisoindoline;
N-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]benzoyl}isoindoline; or
N-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]benzoyl}-5-fluoro-isoindoline
or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 1 which is N-[4-(3-piperidin-1-ylpropoxy)benzoyl]isoindoline or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition which comprises the compound of formula (I) as defined in any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

18 A compound as defined in any one of claims 1 to 16 for use in therapy.

19. A compound as defined in any one of claims 1 to 16 for use in the treatment of neurological diseases.

20. Use of a compound as defined in any one of claims 1 to 16 in the manufacture of a medicament for the treatment of neurological diseases.

21. A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition for use in the treatment of neurological diseases which comprises the compound of formula (I) as defined in any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

23. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)



(II)

with a compound of formula (III)



(III)

or a protected derivative thereof, wherein R^1, R^2, R^3, R^4, a, b, m, n and p are as defined in claim 1 and L is OH or a suitable leaving group; or

(b) preparing a compound of formula (I) wherein R^4 represents $-(CH_2)_q-NR^{11}R^{12}$ which comprises reacting a compound of formula (IV)



(IV)

wherein R^1, R^2, R^3, a, b, m, n, p and q are as defined in claim 1 and L^1 represents a suitable leaving group with a compound of formula $HNR^{11}R^{12}$; wherein R^{11} and R^{12} are as defined in claim 1; and optionally thereafter

(c) deprotecting a compound of formula (I) which is protected; and optionally thereafter

(d) interconversion to other compounds of formula (I).